Resources

1 Resources for

miRNA

Subscribe to this listing via:
RSS
Email

BNET Resources

Glaxo-Regulus Kicks Off an miRNA Land Grab: GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short. New drug technologies -- or "modalities," as the industry...; Tags: Pharmaceutical Company, miRNA, Regulus Therapeutics, Glaxo, Biotechnology, David P. Hamilton; Blog posts 2008-04-18

Additional Resources

QIAGEN Introduces Novel Tools for miRNA Analysis: Company expands portfolio by adding four new sample and assaysolutions for this rapidly emerging area of molecular researchVenlo, The Netherlands - June 25, 2008 - QIAGEN (Nasdaq: QGEN;Frankfurt, Prime Standard: QIA) today announced the launch of fournew research products ...; Articles 2008-06-25
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as...; Articles 2008-06-24
Asuragen to Present Study Results on Differentially Expressed microRNA Biomarkers in Pancreatic FNA and FFPE Specimens, Which Can Distinguish Benign from Malignant Tissues at the Annual Meeting of the European Pancreatic Club in Poland: AUSTIN, Texas -- Today the Company announced that Anna Szafranska, Ph.D., Senior Scientist, will present latest study results on microRNA miRNA biomarkers that distinguish benign pancreatic tissues from malignant tissues at the Joint Meeting of the European Pancreatic Club EPC and the International Association of Pancreatology IAP in Lodz, Poland,...; Articles 2008-06-23
Intradigm Announces Allowance of Key RNA Interference Patent: Patent Covers Small Interfering RNA siRNA Structural Features Tied to Increased Efficacy and Potency of RNAi Therapeutics PALO ALTO, Calif., June 17 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference RNAi therapeutics, today announced that the United States Patent and Trademark Office USPTO...; Articles 2008-06-17

Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center: Summary: Exiqon A/S Today Announces That it has Entered Into a Collaborative Research Agreement With The University of Texas M. D. Anderson Cancer Center to Develop microRNA Based Biomarkers for Breast Cancer VEDBAEK, Denmark, May 27 /PRNewswire-FirstCall/ -- Exiqon A/S, a leading supplier of high-value gene expression...; Articles 2008-05-27
Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe: CARLSBAD, Calif. & BELTSVILLE, Md. -- In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated...; Articles 2008-05-07
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...; Articles 2008-05-06
Asuragen Launches The First Validated microRNA Diagnostic Assay: AUSTIN, Texas -- Asuragen, Inc. announced today the launch of the first microRNA miRNA test for clinical diagnosis and disease management. The assay utilizes qRT-PCR technology* and differentiates between chronic pancreatitis and pancreatic cancer pancreatic ductal adenocarcinoma. Pancreatic cancer is the 4th leading cause of cancer related deaths in the...; Articles 2008-04-23
febit First to Offer miRBase 11.0 Biochip: MEDFORD, Mass. and HEIDELBERG, Germany, April 14 /PRNewswire/ -- febit today announced its newest miRNA Biochip based on the new miRBASE version 11.0 which has been released by the Wellcome Trust Sanger Institute yesterday. The new GeniomR Biochip opens up the most up-to-date scientific information for miRNA microarray experiments....; Articles 2008-04-14
New MicroRNA Analysis Tools From Applied Biosystems Advance Cancer Research: TaqMan[R] Reagents Speed Workflows and Enable Analysis of Trace Amounts of RNA in Cell and Tumor Samples FOSTER CITY, Calif. -- Research related to a class of non-coding small RNA molecules called microRNAs miRNAs is one of the fastest-growing areas in biomedical research. These molecules have been found...; Articles 2008-04-09
Agilent Technologies Expands miRNA Microarray Catalog with New Human, Mouse and Rat Assays: SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE:A) today introduced three new microRNA microarray designs: Human miRNA Microarray v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0. All are based on the Sanger Institute's miRBase 10.1, updated in December 2007. "Researchers tell us that they value specificity...; Articles 2008-04-09
Asuragen Launches Mirna Therapeutics: Asuragen launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics Mirna is Developing "miRNA Replacement" Therapies, Using miRNAs As Drugs to Correct the Down-Regulation Of miRNAs That Occurs in Many Human Cancers AUSTIN, Texas -- Asuragen, Inc. announced today the launch of Mirna Therapeutics, a...; Articles 2008-04-03
RxGen and Santaris Pharma Use LNA-antimiR Technology to antagonize the liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol: HAMDEN, Conn. & H0RSHOLM, Denmark -- In a study published in the journal Nature today, Santaris Pharma and RxGen Inc., a specialty pharma services company demonstrated that a systemically delivered Locked Nucleic Acid LNA compound could safely and effectively silence a microRNA target in African green monkeys. The study shows...; Articles 2008-03-27
Yale and Asuragen Scientists Show That a microRNA Can Reduce Lung Cancer Growth: NEW HAVEN, Conn. & AUSTIN, Texas -- A microRNA miRNA molecule known as let-7 substantially reduced cancer growth in multiple mouse models of lung cancer as reported by researchers at Yale University School of Medicine and Asuragen, Inc. in the journal Cell Cycle. Cancer afflicts 1.5 million people...; Articles 2008-03-25
Yale Scientists Show that a microRNA Can Reduce Lung Cancer Growth.: M2 PRESSWIRE-24 March 2008-Yale University: Yale Scientists Show that a microRNA Can Reduce Lung Cancer GrowthC1994-2008 M2 COMMUNICATIONS LTD RDATE:20032008 New Haven, Conn. -- A small RNA molecule, known as let-7 microRNA miRNA, substantially reduced cancer growth in multiple...; Articles 2008-03-24
The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually From 2005 to 2012: DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c85063) has announced the addition of RNAi 2008 to their offering. This Market Insight Report on RNAi covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions-United...; Articles 2008-03-07
The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually from 2005 to 2012.: M2 PRESSWIRE-6 March 2008-Research and Markets: The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually from 2005 to 2012C1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c85065) has announced the addition of RNAi...; Articles 2008-03-06
Invitrogen Teams with Genisphere to Advance Epigenetic Research: Companies Offer New MicroRNA Labeling and Detection Kits CARLSBAD, Calif. & HATFIELD, Pa. -- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, will become the exclusive provider of fluorescent microRNA microarray labeling kits using Genisphere Inc.'s 3DNA[R] dendrimer signal amplification technology,...; Articles 2008-02-27
Development of a Dual-Luciferase Reporter System for In Vivo Visualization of MicroRNA Biogenesis and Posttranscriptional Regulation: MicroRNAs miRNAs function in mammalian cells via translational repression or messenger RNA mRNA cleavage of target genes by base-pairing with 3' untranslated regions UTRs of target mRNAs. Although miRNAs are involved in cell differentiation or organ development, posttranscritptional regulation of miRNA is not well understood. Here, we developed a dual-luciferase...; Articles 2008-02-01

<< Previous
page 1 of 1
Next >>

Resources

miRNA

BNET Resources

Additional Resources

Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors